2017-08-21 Two abstracts on Phase III COMPASS study with Bayer’s Rivaroxaban accepted for presentation in Hot Line sessions at ESC Congress 2017
2017-08-07 Bayer Receives EU Approval for Stivarga® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer
2017-07-21 Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma
2017-07-21 Bayer’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement
